Anaplastic Thyroid Cancer Clinical Trial
Official title:
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as efatutazone dihydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
PRIMARY OBJECTIVES: I. To determine if the combination of paclitaxel and efatutazone (efatutazone dihydrochloride) improves the confirmed response rate in patients with advanced anaplastic thyroid cancer. SECONDARY OBJECTIVES: I. To estimate the overall survival (OS), duration of response, progression-free survival (PFS), and adverse event rates for the combination of paclitaxel and efatutazone. TERTIARY OBJECTIVES: I. The association of biomarkers with clinical outcome data will be assessed in an exploratory translational analysis. OUTLINE: Patients receive paclitaxel intravenously (IV) over 3 hours on day 1 and efatutazone dihydrochloride orally (PO) twice daily (BID) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 28 days, every 8 weeks until disease progression, and then every 6 months for 5 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04420754 -
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
|
Phase 1 | |
Active, not recruiting |
NCT04552769 -
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Completed |
NCT02688608 -
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
|
Phase 2 | |
Terminated |
NCT00095693 -
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01240590 -
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05819593 -
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
|
||
Active, not recruiting |
NCT04579757 -
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06374602 -
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT06362694 -
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
|
Phase 2 | |
Withdrawn |
NCT01701349 -
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03085056 -
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
|
Early Phase 1 | |
Recruiting |
NCT01774279 -
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
|
||
Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT02244463 -
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05696548 -
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
|
Phase 2 | |
Terminated |
NCT00603941 -
A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel
|
Phase 1/Phase 2 | |
Completed |
NCT00280852 -
Review of Multimodality Management of Anaplastic Thyroid Cancer
|
N/A | |
Recruiting |
NCT04238624 -
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT06079333 -
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
|
Phase 2 |